Gilead's GS 504
Executive Summary
Company begins a second Phase II/III trial of the nucleotide analog for treatment of cytomegalovirus-associated peripheral retinitis in AIDS patients. The study, being conducted by the 11- center Studies of the Ocular Complications of AIDS (SOCA) research group, will enroll 90 patients. Gilead says it has enrolled half of the 48 patients who will participate in the other pivotal trial, which began in January
|
Company begins a second Phase II/III trial of the nucleotide analog for treatment of cytomegalovirus-associated peripheral retinitis in AIDS patients. The study, being conducted by the 11- center Studies of the Ocular Complications of AIDS (SOCA) research group, will enroll 90 patients. Gilead says it has enrolled half of the 48 patients who will participate in the other pivotal trial, which began in January. |